A scientific statement from the National Lipid Association outlines the implications of genetic testing in patients with dyslipidemia.
Treatment with statins for cardiovascular risk reduction is associated with higher levels of insulin resistance in older community-dwelling adults.
Amarin Corporation announced results from the phase 3 REDUCE-IT study of icosapent ethyl (Vascepa) demonstrating a significant reduction in coronary revascularization procedures in high risk patients with mixed dyslipidemia.
Patients with familial hypercholesterolemia were found to be at increased risk for long-term mortality and cardiovascular events after acute myocardial infarction.
Higher intake of whole-fat dairy products is associated with a lower prevalence of metabolic syndrome (MetS) as well as hypertension and diabetes.
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Subcutaneous administration of inclisiran every 6 months was found to reduce low-density lipoprotein cholesterol by 50% in patients with atherosclerotic cardiovascular disease.
Certain components of metabolic syndrome may be more common in patients with Parkinson disease who are carriers of an LRRK2 mutation compared with other PD etiologies.
Treatment with statins was found to reduce the risk for disease recurrence in patients with venous thromboembolism.
Dolutegravir-based regimen may lead to significant improvement in lipids blood concentration, but relevant increases in trunk fat without alterations of body mass index.
In national patient registries, cardiovascular disease risk and diabetes management varied by geographic region in the United States.